China has long been excluded from ICH membership because its recognized drug policies and regulations largely comply with WHO (World Health Organization) standards. And WHO is considered the global minimum standard, while ICH is the lowest in developed countries

On April 28, 2017, the State Food and Drug Administration approved the import and marketing of Dalatavir Hydrochloride Tablets and Asurivir Soft Capsules for the combined treatment of adult chronic hepatitis C. Chronic hepatitis C (CHC) is a common chronic disease in clinical practice

On March 25, AstraZeneca announced that the European Medicines Agency (EMA) officially approved its SGLT-2 inhibitor Forxiga (Dapagliflozin

On October 7, 2021, AbbVie announced that its oral JAK inhibitor upadacitinib (trade name in English: Rinvoq) has become a

Recently, TvardiTherapeutics announced that its oral small molecule STAT3 inhibitor TTI-101 has obtained fast channel qualification from the US FDA for the treatment of recurrent/refractory locally advanced, unresectable, or metastatic diseases

AbbVie today announced that its JAK inhibitor upadacitinib (English trade name Rinvoq), in a phase 2 clinical trial, is used as a single drug or combination therapy to treat red spot wolves